One in seven five-year-olds may not be fully up to date with some routine immunisations, and the UK has lost its ‘measles-free’ status.
News
CR UK, Novartis, Sixth Element team up for hard to treat cancers
The collaboration focuses on the RAS family of genes, which cause more than 30% of all human cancers, including 95% of pancreatic cancers and 45% of colorectal cancers.
NHSE signs ‘definitive’ agreement for Vertex CF drugs
Even more excitingly, clinicians will be able to begin prescribing the drugs – Orkambi, Symkevi and Kalydeco – within just 30 days.
GPs call for ‘better training and tech’ for video consultations
Despite promising uptake figures, only 1% of all current consultations are delivered via video link.
Cosentyx receives EU label update
The drug is the first and only fully-human biologic that directly inhibits interleukin-17A.
Just one week left to get entered into the 2019 Medical & Scientific Excellence Awards
Entry for the 2019 competition will be closing at midnight on Thursday the 31st October.
BMS’ Opdivo, Yervoy show promise in lung cancer
The results build on the benefits the combination has previously shown in various indications.
Electronic prescriptions could save NHS £300m
The final roll-out phase is set to go live on November 18.
Stelara bags positive results in ulcerative colitis
The data were presented at the United European Gastroenterology Week (UEGW) congress.
Success for early MLD gene therapy
The treatment is a cryopreserved formulation of OTL-200.
Janssen seeks to expand Tremfya in arthritis
Up to a third of the 14 million people who are living with psoriasis in Europe will also develop psoriatic arthritis.
Takeda acquires investigational coeliac therapy
The Japanese pharma giant acquired the drug based on results from a phase IIa trial, in which the drug met its primary endpoint.
“Life-changing” diabetes monitors roll-out ahead of schedule
The roll out of the monitors has helped 30,000 people across the country with their type I diabetes
Trikafta wins FDA approval for CF
Approximately 6,000 potential patients will be able to receive the treatment.
PBL given go ahead to advance anthrax vaccine to first phase
The phase I study combines Blue Willow’s novel intra-nasal NanoVax system with PBL’s recombinant protective antigen for anthrax.
